ScPharmaceuticals Inc. (SCPH)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
SCPH Chart
scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John Mohr - Senior Vice President of Clinical Development & Medical Affairs John H. Tucker - President, CEO, Principal Executive Officer & Director Rachael Nokes - Chief Financial Officer Steve C.
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.44 per share a year ago.
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ScPharmaceuticals Inc. (SCPH) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
ScPharmaceuticals Inc. Profile
| - Industry | - Sector | John H. Tucker CEO | NASDAQ (NGS) Exchange | 810648105 CUSIP |
| US Country | 162 Employees | - Last Dividend | - Last Split | 17 Nov 2017 IPO Date |
Overview
scPharmaceuticals Inc. is a progressive pharmaceutical company focused on the innovation and commercialization of a range of pharmaceutical products specifically designed to improve patient care in chronic heart failure and kidney disease. With a concentrated push towards offering ambulatory solutions for fluid congestion, the company leverages advanced drug formulations and drug-device combinations to facilitate home-based treatments. Incorporated in 2013, scPharmaceuticals Inc. has strategically positioned its headquarters in Burlington, Massachusetts, fostering a forward-thinking environment for the development of groundbreaking medical treatments.
Products and Services
- FUROSCIX:
A flagship product candidate of scPharmaceuticals, FUROSCIX is an innovative formulation of furosemide that is administered through an on-body infusor. This pioneering approach targets adults suffering from congestion due to fluid overload, commonly observed in chronic heart failure and kidney disease patients. The formulation enables IV equivalent diuresis to be achieved at home, offering a groundbreaking solution for managing symptoms outside the hospital setting. Additionally, FUROSCIX includes the On-Body Infusor, a sophisticated drug-device combination, emphasizing ease of use and patient convenience.
- SCP-111 (furosemide injection):
Another promising endeavor from scPharmaceuticals, SCP-111 presents a novel pH-neutral aqueous solution of furosemide targeted for subcutaneous administration. This product is in development to facilitate easier, patient-managed treatment schemes outside hospital environments. The formulation enhances the accessibility and applicability of furosemide, a commonly used loop diuretic, underlining the company's commitment to innovation in patient care.
- SCP-111 Autoinjector:
An investigational drug-device fusion, the SCP-111 Autoinjector represents an advanced step in pharmaceutical delivery mechanisms. This single-entity, drug-device combination encompasses a prefilled syringe of SCP-111, neatly incorporated into a commercially available, single-dose, disposable autoinjector. The autoinjector is engineered for simplicity and efficacy, supporting the self-administration of medication in home settings. This development is indicative of scPharmaceuticals' drive towards enhancing drug delivery methods, making treatment more accessible and manageable for patients.
